InfuSystem Holdings stock
INFUAMEXInfuSystem Holdings, Inc., HealthcareISIN US45685K1025
69Score 69 out of 100, Neutral
Price and trend
89 / 100
Price history
+42% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 40% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 58).
The price is 3.2% below its 52-week high. Largest decline in 19 years: 79% (May 2021 to May 2025).
Chart figures for advanced users
- SMA 50$13.33
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$10.58
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)58
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.42
- The lowest closing price of the last twelve months.
- Resistance$15.28
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- InfuSystem Holdings, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $294.58M, is number 90 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $143.44M (up 6.4% year on year) and earnings of $6.63M (up 182.6%).
- MEQIRI Score 69 out of 100 (Neutral): rank 160 of 714 in Healthcare, median 53.
Show more
- The P/E is 33 (Medical (Devices) median 29, own median of recent years 52.4).
- Our model puts fair value at $24.13, with the price 38% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 38% below the fair value of $24.13.Valuation 62
- Earnings turn into cashFree cash flow 141% of earnings over the last 12 months.Fundamentals 72
Weaknesses
- Earnings per share fallingDown 17.9% a year since 2020.Growth 50
- Volatile share priceVolatility 57% a year over the last 12 months.
Its standout strengths are momentum and technical analysis.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $17.24 and expensive above $40.22 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $35.27 (cash-flow model) and $13.00 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $20.96, at 7.8% it would be $28.91.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 2.4% on the twelve months before. Revenue turned from negative at the start of the period to positive ($143.44M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 56%, operating 8%, net 5%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 17 Mar 2027in 125 days
- Last reported
- 5 Nov 2026EPS reported $0.15 (expected $0.13)above expectations
Analyst estimates
Earnings estimates have barely changed since 12 Nov 2026.
- Earnings per share
- $0.490.0%
- Revenue
- $145.48M0.0%
- Earnings per share
- $0.610.0%
- Revenue
- $154.04M0.0%
MEQIRI has stored the estimates since 12 Nov 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at InfuSystem Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger companies by market value
- Metall ZugMETN.SW $460.48M38
- NeuroPaceNPCE $429.74M34
- CerusCERS $428.14M36
- ImplanticaIMP-A-SDB.ST $393.83M49
- StratecSBS.DE $353.7M52
- CapsoVisionCV $333.63M41
- Treace Medical ConceptsTMCI $331.73M48
- SS Innovations InternationalSSII $302.72M28
ETFs that hold InfuSystem Holdings
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.02% | 0.39% | €1.47B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.00% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 8 Aug 2025)
- Valuation signal Undervalued since 11 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.